The Use of Model Organisms in Sterilizing Filtration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Use of Model Organisms in Sterilizing Filtration


Pharmaceutical Technology


The sterilizing filter concept

Until rather recently, it was believed that the sterilization of liquids could be achieved by their filtration through a sterilizing membrane whose proper and pertinent identity was confirmed by its pore-size rating, which was itself determined by integrity testing. The pore-size rating, plotted against organism size, indicated an inverse correlation. However arranged, organism removal by a filter was seen as resulting from the mechanism of size exclusion, also known as sieve retention, wherein the organism is retained because it is larger in size and shape than the filter's pores. The sizes of various organisms are available from listings in the literature, and the size of a filter's largest pores derives from its bubble-point value. Therefore, it was possible to accommodate the size of the restraining pore to the size of the organism to be retained. In the interest of obtaining a maximum flow rate consonant with complete organism removal, the 0.2/0.22-μm-rated membranes were widely accepted as being sterilizing filters.

The sterilizing filter was defined in 1987 by the US Food and Drug Administration on the basis of its retaining a minimum of 1 107 colony-forming units (cfu) of Brevundimonas diminuta (at that time taxonomically identified as Pseudomonas diminuta) per square centimeter of effective filtration area (5).

The situation is complicated in its application by the absence of pore-size rating standards. The pore sizes may not be assumed to have been rated in the same fashion by the various filter manufacturers. Thus, while filters may bear the same pore-size designation, they may not be identical in this regard. Nevertheless, such filters may prove interchangeable in filtration processing operations. Manipulative adaptations often make it possible to substitute one such filter for another.


Limitations of the B. diminuta model
Although the individual rating methods differ, bubble-point measurements performed in as similar a manner as possible enable comparisons to be made among the various types of filters. Given the importance of gauging the sizes of the largest pores, the integrity testing should be as accurate and reproducible as possible. Accordingly, using automated integrity test instruments is recommended, because their use eliminates the subjectivity inherent in manual integrity testing (6). For the same reason, the bubble point should be identified by the straight line plotted from multipoint diffusion measurements extended through and beyond it to a robust flow of air. Single-point diffusive airflow measurements are not sufficiently reliable for this purpose (7).

Advantage of the model organism

There are numerous types and sizes of microorganisms. To explore the sterilizing capabilities of the available filters with each of these different organisms would not be practical and might not even be meaningful from the standpoint of assessing patient risk. Given the large number of organism types and their differences in size, it would be advantageous to select for testing an organism that could serve as a model for all the others, or at least for those commonly encountered in pharmaceutical operations. The smaller the test organism, the more its removal by a filter would ensure the sieve retention of larger organisms. Properties other than size, however, also are important in the selection of the model microbe. Ease and safety in cultivation and handling are real considerations. The likelihood of the selected organisms' being encountered in pharmaceutical operations is another influence on its selection.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here